

Comprehensive characterization of complex linkage structures in a bispecific monoclonal antibody (mAb) using electron activated dissociation (EAD)

Featuring the ZenoTOF 7600 system with EAD from SCIEX and Protein Metrics Inc. software

Andrew Mahan¹, Hirsh Nanda¹, Zoe Zhang²
¹Janssen, Spring House, PA, USA; ²SCIEX, USA

In this technical note a new fragmentation type based on EAD^{1,2} is used to confirm the existence of disulfide and trisulfide linkages as well as free thiols in a bispecific mAb in which 2 different heavy chains and 2 identical light chains are linked. The data were acquired using a 10 Hz data-dependent acquisition (DDA) method and interpreted with Byos software (Protein Metrics Inc.). This workflow demonstrates a routine approach for the streamlined characterization of sulfide-linked peptides with a new level of data quality.

The role of disulfide bonds is essential for maintaining tertiary and/or quaternary structures in proteins. Since the overall structure of proteins is related to their function, it is critical for the safety and efficacy of biotherapeutics to ensure that disulfide bond arrangements are as designed and expected. Existence of trisulfides can affect protein folding, structure and stability. In addition they can further interfere with drug conjugation in case of cysteine-linked protein-drug conjugates. Characterization of linkage arrangements using bottom-up workflows has become increasingly popular due to advances in modern accurate mass spectrometry, novel fragmentation technologies and automated data processing software.^{3,4} However, sulfide bonds prevent effective fragmentation around linked cysteine residues when using collision-induced dissociation (CID), which limits the information available for identifying sulfide-bound peptides as well as sulfide patterns. Although alternative fragmentation

mechanisms exist, these techniques can suffer from long reaction times, low sensitivity and lack of reproducibility.

The data presented in this technical note show a comprehensive analysis of linkage structure, including the confirmation of impurities, such as trisulfide linkages and free thiols. The analysis of linkage structures was performed using DDA of a non-reduced digested bispecific mAb with the ZenoTOF 7600 system (Figure 1). Novel signature fragments were identified to confirm the existence of trisulfides. With this workflow, standard and advanced characterization, leveraging a highly reproducible fragmentation technique based on EAD^{1,2}, is achievable in 1 injection. This workflow enables a streamlined characterization accessible to every user level.

Key features of the ZenoTOF 7600 system

- **Confident confirmation of trisulfide-linked peptides:** The EAD platform method⁵ provides signature fragments to differentiate disulfide and trisulfide linkages, enabling a higher level of structural characterization in 1 injection
- **New depths of peptide mapping analysis:** EAD with fast DDA enables alternative fragmentation for routine, in-depth analysis of next-generation protein therapeutics and standard mAbs
- **Higher MS/MS sensitivity:** Increased detection of fragments (by 5- to 10-fold) using the Zeno trap enables higher confidence in data assignment, which enables free thiol detection at low abundances
- **High reproducibility:** Reproducible fragmentation with EAD for singly, doubly and multiply charged ions enables analysis of more precursors than other alternative and low-reproducibility fragmentation techniques
- **Streamlined and easy to use:** Fully automated data acquisition in DDA mode using EAD with SCIEX OS software and automated data interpretation with Byos software (Protein Metrics Inc.) simplifies the entire user experience



Figure 1. The ZenoTOF 7600 system from SCIEX.

Methods

Sample preparation: The bispecific mAb sample was prepared using the AccuMap Low pH Protein digestion kit (Promega) under non-reducing condition.

Chromatography: A total of 3 μ L (4 μ g) of the Lys-C digest were separated with a Waters ACQUITY CSH C18 column (2.1 \times 100 mm, 1.7 μ m, 130 \AA) using an ExionLC AD system. The mobile phase (A) consisted of water with 0.1% formic acid, while the organic phase (B) was acetonitrile with 0.1% formic acid. A gradient profile was used at a flow rate of 250 μ L/min (Table 1). The column temperature was maintained at 50°C.

Table 1. Chromatography for peptide mapping analysis.

Time [min]	Mobile phase A [%]	Mobile phase B [%]
Initial	99	1.0
5.00	99	1.0
6.00	90	10
65.00	60	40
70.00	40	60
70.50	10	90
74.00	10	90
74.1	99	1.0
75.00	99	1.0
75.10	10	90
79.00	10	90
79.10	99	1.0
83.00	99	1.0

Mass spectrometry: Data were acquired using DDA with the ZenoTOF 7600 system. The electron energy for the alternative fragmentation in the EAD cell was set to a value of 7 eV. Detailed method parameters are summarized in Table 2.

Table 2. Mass spectrometry parameters.

Parameter	MS	MS/MS
Scan mode	TOF MS	IDA dependent
Polarity		positive
Gas 1		50 psi
Gas 2		50 psi
Curtain gas		35 psi
Source temperature		550°C
Ion spray voltage		5500 V
Declustering potential		80 V
Collision energy		12 V
CAD gas		7
Maximum candidate ion		10
Intensity threshold		125 cps
Charge states		2 to 10
Exclusion time		6 s after 2 occurrences
Start mass	200 m/z	100 m/z
Stop mass	2,000 m/z	3,000 m/z
Electron KE	N/A	7 eV
Electron beam current	N/A	4750 nA
ETC	N/A	Dynamic
Zeno trap	N/A	ON
Accumulation time	0.25 s	0.10 s
Time bins to sum	8	12

Data processing: Data were processed using the workflow for disulfide analysis in Byos software (Protein Metrics Inc.).

Overview

Traditional antibody-based therapeutics consist of 2 light chains and 2 heavy chains with multiple interchain and intrachain disulfide bonds to maintain a protein's 3-dimensional structure. Misfolding can lead to a change in protein function such as antigen recognition or binding affinity⁶ and can affect both the efficacy and safety of a biotherapeutic. With the advancement of modern mass spectrometry, bottom-up approaches have become the method of choice for the characterization of multiple product quality attributes, enabling the simultaneous identification and localization of modifications, including characterization of disulfide bonds.^{4,7} The most used fragmentation approach for this workflow (CID) typically leads to peptide backbone fragments while leaving the disulfide bonds intact. This can result in a complicated, yet incomplete MS/MS spectrum that is difficult to interpret. In addition, CID struggles to obtain high fragment coverage for long disulfide-linked peptides, especially around the residues close to the cysteine linkages. Confidently identifying low-abundance disulfide scrambling events can therefore be challenging with CID.

While alternative fragmentation techniques have been used for these analyses in the past, their adoption by the biopharmaceutical industry has been limited by their overall low sensitivity and lack of automated DDA workflows.⁸⁻¹⁰

Disulfide-bonded peptides

The study presented here focused on the detailed characterization of complex sulfide linkages in a multispecific mAb using the ZenoTOF 7600 system. To minimize disulfide scrambling introduced during sample preparation, all free cysteines were capped with N-ethylmaleimide (NEM) followed by digestion with Lys-C using a low pH digest kit. The low pH minimizes any rearrangements of disulfide bonds during the digestion procedure. Fragmentation and identification data from DDA with either Zeno EAD or Zeno CID were compared. Information gained from this comparison was used to establish a routine method for complicated linkage determination. Both EAD and CID were able to identify all expected disulfide linkages from the bispecific mAb, while EAD provided a higher MS/MS coverage for long peptides.

Figure 2 shows an example of typical EAD and CID MS/MS spectra for a regularly sized disulfide-linked peptide with a molecular weight (MW) of 3,536 Da. Both, EAD and CID, achieved a high MS/MS coverage for this linked peptide (97% for EAD and 90% for CID). Among the dominant fragments observed in the EAD spectrum are the charge states +1 and +2 of the 2 corresponding peptides (green labels of peptide 1 and peptide 2 in Figure 2, top) derived from cleavage of the disulfide bond with EAD. That additional level of information obtained by

EAD enables confirmation of the identity of the connected peptides, ruling out potential misassignments, especially in the case of low-abundance scrambled disulfide bonds. Figure 3 demonstrates an example of EAD and CID MS/MS spectra from a large and highly charged disulfide-linked peptide at m/z 952.617 with $z = +8$ and a MW of 7,612 Da. While CID is effective in fragmenting the termini of the connected peptides, the technique struggles to effectively dissociate the peptide backbones towards the center of the long sequences (red circles in Figure 3 right, bottom).




Figure 2. MS/MS spectra for an intrachain disulfide bond from the heavy chain. EAD spectrum (top), CID spectrum (bottom).




Figure 3. Data for disulfide-linked peptide with $z = +8$. TOF MS data for precursor with $z = 8$ (left hand side). EAD MS/MS and CID MS/MS spectra on the right hand side. EAD spectrum provides a much higher fragment coverage compared to CID spectra.

Adversely, EAD can achieve a much more complete fragment coverage throughout the peptide backbone (Figure 3 right, top). For this disulfide peptide, Zeno EAD provided a 73% fragment coverage while Zeno CID only achieved a 45%, proving the higher fragmentation efficiency of EAD for long peptides compared to CID.

Identification of free thiols

Correct disulfide assembly is essential for protein function. However, free thiols are frequently observed in protein therapeutics⁷ in low abundance. These patterns can result from incomplete processing during expression, or chemical cleavage under reducing conditions.⁸ To accurately identify existing free thiols, NEM is used as a capping agent to protect all existing free cysteines before enzymatic digestion. The capping agent introduces a 125 Da increase of the MW. Here, a low amount of free thiols were detected at different cysteine sites of the bispecific mAb sample. Figure 4 is an example of a peptide containing a free cysteine in the conserved region of the heavy chain of the bispecific mAb. Both Zeno EAD (Figure 4, top) and Zeno CID (Figure 4, bottom) provided highly descriptive spectra with full fragment coverage, which confirm the existence of a free thiol at the cysteine in this peptide. The fragments $c7$, $z4$ in the EAD spectrum and $y4$, $y5$, etc. in the CID spectrum all show a +125 amu increase, which can be attributed to the NEM capping of the free thiol. Besides the high level of sequence confirmation,

EAD spectra also offer the ability to differentiate leucine (Leu) from iso-leucine (Ile) as shown in detail previously.⁹ In this particular peptide, 2 Leu residues present based on the theoretical sequence. Fragments $z6-43$ and $z3-43$ were detected in the MS/MS spectrum (encircled fragments in Figure 4, top), which verify that these 2 amino acids are both Leu. No evidence for Ile was found for this peptide.

Trisulfide-bonded peptides

Trisulfide bonds are formed by the insertion of an additional sulfur into a disulfide bond, causing a shift of the MW 32 Da. Although it is reported that trisulfides have no effect on antigen binding or on the stability of the therapeutic molecule⁶, they are known to change protein folding and may cause challenges in case of additional bioengineering processes. Therefore, the identification and close monitoring of this post-translational modification is necessary. A high abundance of trisulfides was detected in the studied molecule at the interchain disulfide bond between heavy and light chains. As expected for trisulfide-bonded peptides, a 32 Da increase was observed for the MW of the precursor compared to the disulfide-bonded peptide. Further evidence was found using MS/MS information. Figure 5 shows the comparison of the MS/MS spectra of the disulfide- and trisulfide-containing peptide using CID. As the precursor is triply charged, a 10.67 amu increase was observed in the spectrum of the trisulfide-bonded peptide. Meanwhile the $y5++$ fragments




Figure 4. Identification of free thiol in a doubly charged peptide with both, EAD and CID. The free cysteines were capped with NEM. In addition to obtaining a full fragment coverage, EAD provided confirmation of leucines by diagnostic *w*-ions (encircled ions).

presented a 16 amu shift. The EAD spectrum for the trisulfide containing peptide is shown in Figure 6. As previously discussed, EAD can dissociate disulfide bonds, resulting in signals for the 2 cleaved peptides in the MS/MS spectrum.¹⁰ Furthermore, EAD can dissociate trisulfide bonds, leading to 4 different fragments: peptide 1, peptide 1+sulfur, peptide 2, peptide 2+sulfur (Figure 7). While the signals for peptide 1 and peptide 2 in the MS/MS spectrum give further confidence in the identity of both linked peptides, the fragments of the respective peptide with additional sulfur can be used as diagnostic ions to confirm the existence of trisulfide bonds with very high confidence. Neither of these fragments can be obtained by CID.




Figure 5. CID MS/MS spectra for an interchain disulfide-linked peptide (top) and the peptide with an interchain trisulfide (bottom). The precursor mass (indicated as M in the spectra) shows an *m/z* difference of 10.67 amu, which corresponds to a mass difference of 32 Da in the case of a triply charged precursor. This difference can be linked to an additional sulfur (trisulfide bond). The corresponding *m/z* shift of 16 amu can also be observed for the doubly-charged the *y*₅-ion.




Figure 6. EAD MS/MS spectrum for interchain trisulfide-linked peptide. The peptides shown contain an interchain disulfide bond between heavy chain and light chain. Insets show evidence of both peptides 1 and 2, and each of the peptides with an additional m/z shift of 32 amu corresponding to an additional sulfur, which increases the confidence in the correct identification of a trisulfide bond.




Figure 7. Schematic of the dissociation of a trisulfide-bond with EAD.

Conclusions

- The existence of trisulfide bonds was confidently confirmed through signature ions generated by DDA with Zeno EAD: a 1-injection platform method without the need for optimization
- Confident sequence and disulfide linkage confirmation of long disulfide-bonded peptides were achieved with EAD, showing superior fragmentation coverage compared to CID
- Free thiols were detected at low levels with high confidence using EAD, even in case of low-charged precursors
- In addition to studying sulfide arrangements, amino acid isomers can be differentiated with the same Zeno EAD data, enabling high efficiency to obtain a wealth of information on the analyte of interest
- Automatic, state-of-the-art data processing enables the routine and advanced characterization of complex biotherapeutics and standard mAbs in a reproducible manner using Byos software from Protein Metrics Inc.

References

1. Baba, T. et al. (2015) Electron capture dissociation in a branched radio-frequency ion trap, [Anal. Chem. 87\(1\), 785–792.](#)
2. Baba, T. et al. (2021) Dissociation of biomolecules by an intense low-energy electron beam in a high sensitivity time-of-flight mass spectrometer. [J. Am. Soc. Mass Spectrom. 32\(8\), 1964–1975.](#)
3. Srebalus Barnes, C.A. et al. (2007) Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. [Mass Spectrom. Rev. 26\(3\), 370–388.](#)
4. Lakbub, J.C. et al. (2018) Recent mass spectrometry-based techniques and considerations for disulfide bond characterization in proteins. [Anal. Bioanal Chem. 410\(10\), 2467–2484.](#)
5. An evaluation of a single injection platform method for advanced characterization of protein therapeutics using electron activation dissociation (EAD). [SCIEX technical note, RUO-MKT-02-13965-A.](#)
6. Gu, Sheng, Pepinsky R et al. (2010) Characterization of trisulfide modification in antibody. [Anal Biochem 400\(1\):89-98.](#)
7. Devarie Baez N, Furdui C et al. (2015) Mass Spectrometry in Studies of Protein Thiol Chemistry and Signaling: Opportunities and Caveats. [Free Radic Biol Med. 80: 191-211.](#)
8. Chapter 1.4 Analysis of Disulfide Bond Formation in Therapeutic Proteins. [Oxidative folding of proteins: basic principles, Cellular Regulation and Engineering, 2018.](#)
9. Comprehensive peptide mapping of biopharmaceuticals utilizing electron activation dissociation (EAD). [SCIEX technical note, RUO-MKT-02-12639-B.](#)
10. Confirmation of disulfide linkages in adalimumab using electron activated dissociation (EAD). [SCIEX technical note, RUO-MKT-02-12913-B.](#)

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2022 DH Tech. Dev. Pte. Ltd. RUO-MKT-02-14373-A



Headquarters
500 Old Connecticut Path | Framingham, MA 01701 USA
Phone 508-383-7700
sciex.com

International Sales
For our office locations please call the division headquarters or refer to our website at sciex.com/offices